{"nctId":"NCT00366249","briefTitle":"Study Evaluating the Safety and Efficacy of a Once-daily Dose of Tigecycline vs Ertapenem in Diabetic Foot Infections (DFI) With a Substudy in Patients With Diabetic Foot Infections Complicated by Osteomyelitis.","startDateStruct":{"date":"2007-01"},"conditions":["Bacterial Infections","Diabetic Foot","Osteomyelitis"],"count":1061,"armGroups":[{"label":"A","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Tigecycline"]},{"label":"B","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Ertapenem"]}],"interventions":[{"name":"Tigecycline","otherNames":[]},{"name":"Ertapenem","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Main inclusion criteria:\n\n* Men and women aged 18 or older with diabetes and a qualifying foot infection. People with evidence of a diabetic foot infection with osteomyelitis may qualify for the osteomyelitis substudy arm.\n\nMain exclusion criteria:\n\n* People with additional significant disease, infection with resistant pathogens, contraindication, or hypersensitivity to any test article or related antibiotic.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Patients With Clinical Response of Cure Vs. Failure.","description":"Cure: Recovery so no added antibiotic therapy. Failure: Added antibiotic therapy for no response or worsening after improvement, new purulence, \\>120% doses, non-routine surgical treatment or death related to Diabetic Foot Infections (DFI) \\> 48 hrs.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"316","spread":null},{"groupId":"OG001","value":"334","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"71","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Clinical Response of Cure Vs. Failure Assessed at Least 25 - 27 Weeks Post Last Dose.","description":"Cure: Recovery so no added antibiotic therapy. Failure: Added antibiotic therapy for no response or worsening after improvement, new purulence, \\>120% doses, non-routine surgical treatment or death related to DFI \\> 48 hrs.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Patients With Clinical Response of Cure Vs. Failure/Indeterminate.","description":"Cure: Recovery so no added antibiotic therapy. Failure: Added antibiotic therapy for no response or worsening after improvement, new purulence, \\>120% doses, non-routine surgical treatment or death related to DFI \\> 48 hrs. Indeterminate: Lost to follow-up, death\\<48 hours or noninfection related.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"340","spread":null},{"groupId":"OG001","value":"363","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"117","spread":null},{"groupId":"OG001","value":"86","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Clinical Response of Cure Vs. Failure/Indeterminate Assessed at Least 25 - 27 Weeks Post Last Dose.","description":"Cure: Recovery so no added antibiotic therapy. Failure: Added antibiotic therapy for no response or worsening after improvement, new purulence, \\>120% doses, non-routine surgical treatment or death related to DFI \\> 48 hrs. Indeterminate: Lost to follow-up, death\\<48 hours or noninfection related.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Microbiologic Response of Eradication.","description":"Eradication defined as: no pathogen is present in the repeat culture from the original site of infection, or a clinical response of the cure precludes the availability of a specimen for culture.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"209","spread":null},{"groupId":"OG001","value":"229","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":79},"commonTop":["Nausea","Vomiting","Diarrhea","Hypertension","Hypoglycemia"]}}}